Acadia Pharmaceuticals (ACAD) Cash & Current Investments (2010 - 2026)

Acadia Pharmaceuticals' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $851.5 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 24.92% year-over-year to $851.5 million; the TTM figure through Mar 2026 stood at $851.5 million (up 24.92% YoY), while the FY2025 annual figure was $819.7 million, up 8.43% from the prior year.
• Cash & Current Investments was $851.5 million for Q1 2026 at Acadia Pharmaceuticals, up from $819.7 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $851.5 million in Q1 2026 to a low of $345.9 million in Q3 2023.
• Historically, Cash & Current Investments has averaged $562.0 million across 5 years, with a median of $470.5 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Cash & Current Investments slipped 22.81% in 2022, then surged 72.26% in 2024.
• A 5-year view of Cash & Current Investments shows it stood at $416.8 million in 2022, then rose by 5.29% to $438.9 million in 2023, then soared by 72.26% to $756.0 million in 2024, then rose by 8.43% to $819.7 million in 2025, then gained by 3.88% to $851.5 million in 2026.
• The last three Cash & Current Investments figures came in at $851.5 million (Q1 2026), $819.7 million (Q4 2025), and $847.0 million (Q3 2025), per Business Quant data.